Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AgenT-797, Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel in Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma
NCT06251973Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2024
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics, Allogeneic CAR-T, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of agenT-797, botensilimab, balstilimab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2024; status: active, not recruiting.
02
Drugs
agenT-797botensilimabbalstilimab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06251973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251973.